(Q37823322)

23 August 2017

1 reference

title

Optimal use of biologics in the management of Crohn's disease (English)

1 reference

23 August 2017

0 references

1

Remo Panaccione

1 reference

23 August 2017

Subrata Ghosh

2

1 reference

23 August 2017

1 May 2010

1 reference

Therapeutic Advances in Gastroenterology

23 August 2017

1 reference

23 August 2017

3

1 reference

23 August 2017

3

1 reference

23 August 2017

179-189

1 reference

Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Certolizumab pegol for the treatment of Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Infliximab maintenance therapy for fistulizing Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Management of Crohn's disease in adults

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Infliximab for the treatment of fistulas in patients with Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Frequency of glucocorticoid resistance and dependency in Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002580

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1756283X09357579

Management of Crohn's disease in adults

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1756283X09357579

The role of NF-kappaB activation in the pathogenesis of acute pancreatitis.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1756283X09357579

Infliximab dose intensification in Crohn's disease

21 January 2018

1 reference

12 December 2020

Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy

1 reference

12 December 2020

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

1 reference

12 December 2020

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

12 December 2020

Predictors of Crohn's disease

1 reference

12 December 2020

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

12 December 2020

Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial

1 reference

12 December 2020

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756283X09357579

1 reference

23 August 2017

1 reference

PMC publication ID

3002580

23 August 2017

PubMed publication ID

21180600

1 reference

PMC publication ID

3002580